Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 9972 · American Patients First Act of 2026 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395l Payment of benefits

+1 −12 of 3 shown
More for 42 U.S.C. § 1395l
Read § 1395lOnly this section
3 changes the bill asks for here, 2 carried out
  1. Not carried out:

    in subparagraph (S)(i), by striking subject to subparagraph (EE) and inserting subject to subparagraphs (EE) and (II);

    The bill points to subparagraph (S) of § 1395l(a)(1), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no subparagraph (S) in /us/usc/t42/s1395l/a/1
  2. Carried out:

    by striking and (HH) and inserting (HH); and

  3. Carried out:

    by inserting , and (II) with respect to skin substitute products under section 1861(s)(2)(LL) furnished during the period beginning on January 1, 2027, and ending on December 31, 2030, the amount paid shall be 80 percent of the lesser of the actual charge or the payment amount established under section 1847A(b)(1)(D) before the semicolon at the end.

§ 1395l(a)

§ 1395l. Payment of benefits

(a) Amounts Except as provided in section 1395mm of this title, and subject to the succeeding provisions of this section, there shall be paid from the Federal Supplementary Medical Insurance Trust Fund, in the case of each individual who is covered under the insurance program established by this part and incurs expenses for services with respect to which benefits are payable under this part, amounts equal to—

(1) in the case of services described in section 1395k(a)(1) of this title—80 percent of the reasonable charges for the services; except that (A) an organization which provides medical and other health services (or arranges for their availability) on a prepayment basis (and either is sponsored by a union or employer, or does not provide, or arrange for the provision of, any inpatient hospital services) may elect to be paid 80 percent of the reasonable cost of services for which payment may be made under this part on behalf of individuals enrolled in such organization in lieu of 80 percent of the reasonable charges for such services if the organization undertakes to charge such individuals no more than 20 percent of such reasonable cost plus any amounts payable by them as a result of subsection (b), (B) with respect to items and services described in section 1395x(s)(10)(A) of this title, the amounts paid shall be 100 percent of the reasonable charges for such items and services, (C) with respect to expenses incurred for those physicians’ services for which payment may be made under this part that are described in section 1395y(a)(4) of this title, the amounts paid shall be subject to such limitations as may be prescribed by regulations, (D) with respect to clinical diagnostic laboratory tests for which payment is made under this part (i)(I) on the basis of a fee schedule under subsection (h)(1) (for tests furnished before January 1, 2017) or subsection (d)(1) or (aa) of section 1395m of this title, the amount paid shall be equal to 80 percent (or 100 percent, in the case of such tests for which payment is made on an assignment-related basis) of the lesser of the amount determined under such fee schedule, the limitation amount for that test determined under subsection (h)(4)(B), or the amount of the charges billed for the tests, or (II) under section 1395m–1 of this title (for tests furnished on or after January 1, 2017), the amount paid shall be equal to 80 percent (or 100 percent, in the case of such tests for which payment is made on an assignment-related basis) of the lesser of the amount determined under such section or the amount of the charges billed for the tests, or (ii) for tests furnished before January 1, 2017, on the basis of a negotiated rate established under subsection (h)(6), the amount paid shall be equal to 100 percent of such negotiated rate,, (E) with respect to services furnished to individuals who have been determined to have end stage renal disease, the amounts paid shall be determined subject to the provisions of section 1395rr of this title, (F) with respect to clinical social worker services under section 1395x(s)(2)(N) of this title, the amounts paid shall be 80 percent of the lesser of (i) the actual charge for the services or (ii) 75 percent of the amount determined for payment of a psychologist under clause (L), (G) with respect to facility services furnished in connection with a surgical procedure specified pursuant to subsection (i)(1)(A) and furnished to an individual in an ambulatory surgical center described in such subsection, for services furnished beginning with the implementation date of a revised payment system for such services in such facilities specified in subsection (i)(2)(D), the amounts paid, subject to subsection (i)(9), shall be 80 percent of the lesser of the actual charge for the services or the amount determined by the Secretary under such revised payment system, (H) with respect to services of a certified registered nurse anesthetist under section 1395x(s)(11) of this title, the amounts paid shall be 80 percent of the least of the actual charge, the prevailing charge that would be recognized (or, for services furnished on or after January 1, 1992, the fee schedule amount provided under section 1395w–4 of this title) if the services had been performed by an anesthesiologist, or the fee schedule for such services established by the Secretary in accordance with subsection (l), (I) with respect to covered items (described in section 1395m(a)(13) of this title), the amounts paid shall be the amounts described in section 1395m(a)(1) of this title, and (J) with respect to expenses incurred for radiologist services (as defined in section 1395m(b)(6) of this title), subject to section 1395w–4 of this title, the amounts paid shall be 80 percent of the lesser of the actual charge for the services or the amount provided under the fee schedule established under section 1395m(b) of this title, (K) with respect to certified nurse-midwife services under section 1395x(s)(2)(L) of this title, the amounts paid shall be 80 percent of the lesser of the actual charge for the services or the amount determined by a fee schedule established by the Secretary for the purposes of this subparagraph (but in no event shall such fee schedule exceed 65 percent of the prevailing charge that would be allowed for the same service performed by a physician, or, for services furnished on or after January 1, 1992, 65 percent (or 100 percent for services furnished on or after January 1, 2011) of the fee schedule amount provided under section 1395w–4 of this title for the same service performed by a physician), (L) with respect to qualified psychologist services under section 1395x(s)(2)(M) of this title, the amounts paid shall be 80 percent of the lesser of the actual charge for the services or the amount determined by a fee schedule established by the Secretary for the purposes of this subparagraph, (M) with respect to prosthetic devices and orthotics and prosthetics (as defined in section 1395m(h)(4) of this title), the amounts paid shall be the amounts described in section 1395m(h)(1) of this title, (N) with respect to expenses incurred for physicians’ services (as defined in section 1395w–4(j)(3) of this title) other than personalized prevention plan services (as defined in section 1395x(hhh)(1) of this title), the amounts paid shall be 80 percent of the payment basis determined under section 1395w–4(a)(1) of this title, (O) with respect to services described in section 1395x(s)(2)(K) of this title (relating to services furnished by physician assistants, nurse practitioners, or clinic nurse specialists), the amounts paid shall be equal to 80 percent of (i) the lesser of the actual charge or 85 percent of the fee schedule amount provided under section 1395w–4 of this title, or (ii) in the case of services as an assistant at surgery, the lesser of the actual charge or 85 percent of the amount that would otherwise be recognized if performed by a physician who is serving as an assistant at surgery, (P) with respect to surgical dressings, the amounts paid shall be the amounts determined under section 1395m(i) of this title, (Q) with respect to items or services for which fee schedules are established pursuant to section 1395u(s) of this title, the amounts paid shall be 80 percent of the lesser of the actual charge or the fee schedule established in such section, (R) with respect to ambulance services, (i) the amounts paid shall be 80 percent of the lesser of the actual charge for the services or the amount determined by a fee schedule established by the Secretary under section 1395m(l) of this title and (ii) with respect to ambulance services described in section 1395m(l)(8) of this title, the amounts paid shall be the amounts determined under section 1395m(g) of this title for outpatient critical access hospital services, (S)(i) except as provided in clause (ii), subject to subparagraph (EE), with respect to drugs and biologicals (including intravenous immune globulin (as defined in section 1395x(zz) of this title)) not paid on a cost or prospective payment basis as otherwise provided in this part (other than items and services described in subparagraph (B)), the amounts paid shall be 80 percent of the lesser of the actual charge or the payment amount established in section 1395u(o) of this title (or, if applicable, under section 1395w–3, 1395w–3a, or 1395w–3b of this title), and (ii) with respect to insulin furnished on or after July 1, 2023, through an item of durable medical equipment covered under section 1395x(n) of this title, the amounts paid shall be, subject to the fourth sentence of this subsection, 80 percent of the payment amount established under section 1395w–3a of this title (or section 1395w–3b of this title, if applicable) for such insulin, (T) with respect to medical nutrition therapy services (as defined in section 1395x(vv) of this title), the amount paid shall be 80 percent (or 100 percent if such services are recommended with a grade of A or B by the United States Preventive Services Task Force for any indication or population and are appropriate for the individual) of the lesser of the actual charge for the services or 85 percent of the amount determined under the fee schedule established under section 1395w–4(b) of this title for the same services if furnished by a physician, (U) with respect to facility fees described in section 1395m(m)(2)(B) of this title, the amounts paid shall be 80 percent of the lesser of the actual charge or the amounts specified in such section, (V) notwithstanding subparagraphs (I) (relating to durable medical equipment), (M) (relating to prosthetic devices and orthotics and prosthetics), and (Q) (relating to 1395u(s) items), with respect to competitively priced items and services (described in section 1395w–3(a)(2) of this title) that are furnished in a competitive area, the amounts paid shall be the amounts described in section 1395w–3(b)(5) of this title, (W) with respect to additional preventive services (as defined in section 1395x(ddd)(1) of this title), the amount paid shall be (i) in the case of such services which are clinical diagnostic laboratory tests, the amount determined under subparagraph (D) (if such subparagraph were applied, by substituting “100 percent” for “80 percent”), and (ii) in the case of all other such services, 100 percent of the lesser of the actual charge for the service or the amount determined under a fee schedule established by the Secretary for purposes of this subparagraph, (X) with respect to personalized prevention plan services (as defined in section 1395x(hhh)(1) of this title), the amount paid shall be 100 percent of the lesser of the actual charge for the services or the amount determined under the payment basis determined under section 1395w–4 of this title, (Y) subject to subsection (dd), with respect to preventive services described in subparagraphs (A) and (B) of section 1395x(ddd)(3) of this title that are appropriate for the individual and, in the case of such services described in subparagraph (A), are recommended with a grade of A or B by the United States Preventive Services Task Force for any indication or population, the amount paid shall be 100 percent of (i) except as provided in clause (ii), the lesser of the actual charge for the services or the amount determined under the fee schedule that applies to such services under this part, and (ii) in the case of such services that are covered OPD services (as defined in subsection (t)(1)(B)), the amount determined under subsection (t), (Z) with respect to Federally qualified health center services for which payment is made under section 1395m(o) of this title, the amounts paid shall be 80 percent of the lesser of the actual charge or the amount determined under such section, (AA) with respect to an applicable disposable device (as defined in paragraph (2) of section 1395m(s) of this title) furnished to an individual pursuant to paragraph (1) of such section, the amount paid shall be equal to 80 percent of the lesser of the actual charge or the amount determined under paragraph (3) of such section, (BB) with respect to home infusion therapy, the amount paid shall be an amount equal to 80 percent of the lesser of the actual charge for the services or the amount determined under section 1395m(u) of this title, (CC) with respect to opioid use disorder treatment services furnished during an episode of care, the amount paid shall be equal to the amount payable under section 1395m(w) of this title less any copayment required as specified by the Secretary, (DD) with respect to a specified COVID–19 testing-related service described in paragraph (1) of subsection (cc) for which payment may be made under a specified outpatient payment provision described in paragraph (2) of such subsection, the amounts paid shall be 100 percent of the payment amount otherwise recognized under such respective specified outpatient payment provision for such service, (EE) with respect to a part B rebatable drug (as defined in paragraph (2) of section 1395w–3a(i) of this title) furnished on or after April 1, 2023, for which the payment amount for a calendar quarter under paragraph (3)(A)(ii)(I) of such section (or, in the case of a part B rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title for which, the payment amount described in section 1395w–3a(b)(1)(B) of this title) for such drug for such quarter exceeds the inflation-adjusted payment under paragraph (3)(A)(ii)(II) of such section for such quarter, the amounts paid shall be equal to the percent of the payment amount under paragraph (3)(A)(ii)(I) of such section or section 1395w–3a(b)(1)(B) of this title, as applicable, that equals the difference between (i) 100 percent, and (ii) the percent applied under section 1395w–3a(i)(5)(B) of this title (FF) with respect to marriage and family therapist services and mental health counselor services under section 1395x(s)(2)(II) of this title, the amounts paid shall be 80 percent of the lesser of the actual charge for the services or 75 percent of the amount determined for payment of a psychologist under subparagraph (L), (GG) with respect to lymphedema compression treatment items (as defined in section 1395x(mmm) of this title), the amount paid shall be equal to 80 percent of the lesser of the actual charge or the amount determined under the payment basis determined under section 1395m(z) of this title, [struck: and ](HH) with respect to items and services related to the administration of intravenous immune globulin furnished on or after January 1, 2024, as described in section 1395x(zz) of this title, the amounts paid shall be the lesser of the 80 percent of the actual charge or the payment amount established under section 1395u(o)(8) of this title[inserted: , and (II) with respect to skin substitute products under section 1861(s)(2)(LL) furnished during the period beginning on January 1, 2027, and ending on December 31, 2030, the amount paid shall be 80 percent of the lesser of the actual charge or the payment amount established under section 1847A(b)(1)(D)];

(2) in the case of services described in section 1395k(a)(2) of this title (except those services described in subparagraphs (C), (D), (E), (F), (G), (H), and (I) of such section and unless otherwise specified in section 1395rr of this title)—

(A) with respect to home health services (other than a covered osteoporosis drug) (as defined in section 1395x(kk) of this title), the amount determined under the prospective payment system under section 1395fff of this title;

Rest of § 1395l unchanged ·

42 U.S.C. § 1395m Special payment rules for particular items and services

+80 −0Shown
More for 42 U.S.C. § 1395m
Read § 1395mOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1834 of the Social Security Act (42 U.S.C. 1395m) is amended by adding at the end the following new subsection:(bb) Special payment rules for skin substitute products.— (1) Prepayment claim review and prior authorization.— (A) Initial prepayment claim review for certain providers.— (i) In general.— Beginning January 1, 2027, the Secretary shall conduct prepayment review of claims for …

§ 1395m(aa)–(bb)

Start of § 1395m to (aa)(2)(B)(i) unchanged ·

(ii) for a succeeding year, the age specified in this subparagraph for the preceding year, increased by 1 year.

(C) Standards following USPSTF rating of A or B In the case of a multi-cancer early detection screening test that is recommended with a grade of A or B by the United States Preventive Services Task Force, beginning on the date on which coverage for such test is provided pursuant to section 1395x(ddd)(1) of this title, the preceding provisions of this paragraph shall not apply.

(bb) [inserted: Special payment rules for skin substitute products.—]

(1) [inserted: Prepayment claim review and prior authorization.—]

(A) [inserted: Initial prepayment claim review for certain providers.—]

(i) [inserted: In general.—] [inserted: Beginning January 1, 2027, the Secretary shall conduct prepayment review of claims for skin substitute products submitted under this title by a specified provider of skin substitute products unless 1 or more of the conditions described in clause (ii) is met with respect to such provider.]

(ii) [inserted: Limitation.—] [inserted: For purposes of clause (i), the conditions described in this subparagraph are, with respect to a specified provider of skin substitute products, the following:]

(I) [inserted: Skin substitute products furnished by the provider are subject to prior authorization under subparagraph (B).]

(II) [inserted: The rate of approval for claims for skin substitute products furnished by such provider that are subject to prepayment review under this subparagraph exceeds 90 percent (as determined over a period of time or number of claims specified by the Secretary).]

(III) [inserted: The Secretary determines that the billing practices of the provider are consistent with the applicable coverage criteria and requirements under this title.]

(B) [inserted: Prior authorization for specified providers of skin substitute products.—]

(i) [inserted: In general.—] [inserted: Beginning not later than January 1, 2028, subject to clause (ii), the Secretary shall, for a period of 180 days, apply prior authorization for skin substitute products that are furnished by a specified provider of skin substitute products.]

(ii) [inserted: Removal from prior authorization.—] [inserted: In the event that the Secretary determines, with respect to a specified provider of skin substitute products, that the rate of approval for requests for prior authorization under this subparagraph for skin substitute products furnished by such provider exceeds 90 percent (as determined over a period of time or number of claims specified by the Secretary), the Secretary shall cease to apply prior authorization under this paragraph for skin substitute products furnished by such provider.]

(C) [inserted: Enrollment revocation or exclusion of noncompliant outlier providers.—]

(i) [inserted: In general.—] [inserted: Beginning January 1, 2029, if the rate of denial (as determined after the exhaustion of all appeals and reviews) for requests for prior authorization under subparagraph (B) for skin substitute products furnished by an outlier provider of skin substitute products exceeds 75 percent over a period of 6 or more consecutive months, the Secretary shall determine that an abuse of billing privileges exists with respect to such provider for purposes of section 424.535(a)(8)(ii) of title 42, Code of Federal Regulations.]

(ii) [inserted: Referral for exclusion.—] [inserted: If the Secretary determines under clause (i) that an abuse of billing privileges exists with respect to an outlier provider of skin substitute products, the Secretary shall direct the Inspector General of the Department of Health and Human Services to determine whether such provider should be excluded from participation in any Federal health care program under section 1128(b)(6).]

(D) [inserted: Specified provider of skin substitute products defined.—]

(i) [inserted: In general.—] [inserted: For purposes of this paragraph, the term “specified provider of skin substitute products” means—]

(I) [inserted: an outlier provider of skin substitute products, as determined under clause (ii);]

(II) [inserted: a provider with respect to which, of all claims for payment under this title submitted in the preceding year, 15 percent or more of such claims were for the provision of skin substitute products; and]

(III) [inserted: as the Secretary determines appropriate, a provider of skin substitute products that—]

(aa) [inserted: is newly enrolled under section 1866(j);]

(bb) [inserted: has undergone a change in ownership during the preceding year;]

(cc) [inserted: is a high risk provider (as determined by the Secretary under section 424.518 of title 42, Code of Federal Regulations); or]

(dd) [inserted: has a pattern or practice of noncompliance with conditions of participation under this title or a high percentage of previously denied claims (as determined by the Secretary).]

(ii) [inserted: Identification of outlier providers of skin substitute products.—]

(I) [inserted: In general.—] [inserted: Not later than December 1, 2026, and every 2 years thereafter through December 1, 2036, the Secretary shall determine the 3 percent of the total number of providers of skin substitute products that are outlier providers of skin substitute products.]

(II) [inserted: Outlier providers of skin substitute products.—] [inserted: The determination of an outlier provider of skin substitute products under this paragraph shall be based upon the providers (as identified by national provider identification number) that received the greatest total payment under this title for skin substitute products furnished in the year preceding the year in which the determination under subclause (I) is made.]

(III) [inserted: Referral to OIG.—] [inserted: The Secretary shall—]

(aa) [inserted: make publicly available the list of outlier providers of skin substitute products identified under each determination under subclause (I); and]

(bb) [inserted: transmit such list to the Inspector General of the Department of Health and Human Services for the assessment of potential fraud, waste, or abuse.]

(E) [inserted: Funding.—] [inserted: For purposes of carrying out this paragraph, the Secretary shall provide for the transfer, from the Federal Supplementary Medical Insurance Trust Fund under section 1841, to the Centers for Medicare & Medicaid Services Program Management Account, of $2,500,000 for each of fiscal years 2028 through 2031, to remain available until expended.]

(2) [inserted: Medicare coverage criteria for skin substitute products.—] [inserted: Any skin substitute product furnished during 2027 shall be subject to the same coverage criteria when determining whether the skin substitute product is covered under section 1862(a)(1)(A), unless such product is determined by the Secretary to be unsafe based on evidence of contamination, serious infectious disease, or serious adverse reactions caused by the product. Neither the Secretary nor any Medicare administrative contractor may determine, including through a determination made pursuant to the prepayment review program or prior authorization program described in paragraphs (2) and (3), that a specific skin substitute product furnished in 2027 is not covered under this title based solely on analysis of the clinical evidence relating to that skin substitute product.]

(3) [inserted: Skin substitute product wastage.—]

(A) [inserted: In general.—] [inserted: With respect to skin substitute products furnished for the treatment of chronic or acute wounds, payment may only be made under this title for the reasonable and necessary portion of the skin substitute product used in the treatment of the wound, excluding wastage.]

(B) [inserted: Reasonable and necessary defined.—] [inserted: For the purpose of subparagraph (A), the term “reasonable and necessary portion of the skin substitute product” means the greater of—]

(i) [inserted: 350 square centimeters; or]

(ii) [inserted: 120 percent of the size of the treated wound.]

(4) [inserted: Limitation on repeated applications.—] [inserted: Payment may not be made under this title for more than 3 distinct applications of a skin substitute product with respect to the same wound if, in the clinical judgment of the provider furnishing such product, there has been no improvement in the wound.]

(5) [inserted: Certification requirement.—] [inserted: Payment may only be made under this title for a skin substitute product if the provider furnishing such product is certified—]

(A) [inserted: by the American Board of Wound Management as a certified wound specialist or a certified wound care specialist physician;]

(B) [inserted: by the Wound, Ostomy and Continence Nursing Certification Board as a certified wound care nurse practitioner;]

(C) [inserted: by the National Alliance of Wound Care and Ostomy as wound care certified; or]

(D) [inserted: by the American Foot Care Nurses Association as a certified foot care specialist.]

(6) [inserted: Limitation on provider discounts.—] [inserted: For the period beginning on January 1, 2027, and ending on December 31, 2030, payment may not be made under this title for a skin substitute product if the provider furnishing such product obtained such product for less than $342.75 per square centimeter.]

(7) [inserted: Skin substitute product defined.—] [inserted: In this subsection, the term “skin substitute product” has the meaning given such term in section 1847A(c)(6)(J).]

42 U.S.C. § 1395w–3a Use of average sales price payment methodology

+41 −610 of 11 shown
More for 42 U.S.C. § 1395w–3a
Read § 1395w–3aOnly this section
11 changes the bill asks for here, 10 carried out
  1. Carried out:

    by striking the period at the end and inserting ; and;

  2. Carried out:

    by striking shall apply to and inserting(A) to shall apply—; and

  3. Carried out:

    by adding at the end the following new subparagraph:(B) to payment for skin substitute products (as defined in subsection (c)(6)(J)) that are furnished during the period beginning on January 1, 2027, and ending on December 31, 2030.; and

  4. Not carried out:

    in the text preceding subparagraph (A), by inserting or a skin substitute product after drug or biological;

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: in the text preceding subparagraph (X), by inserting QTEXT after QTEXT;
  5. Carried out:

    in subparagraph (B), by striking or at the end;

  6. Carried out:

    in subparagraph (C), by striking the period at the end and inserting ; or; and

  7. Carried out:

    by adding at the end the following new subparagraph:(D) in the case of a skin substitute product (as defined in subsection (c)(6)(J)) furnished during the period beginning on January 1, 2027, and ending on December 31, 2030, $457 per square centimeter.; and

  8. Carried out:

    in subparagraph (A), by inserting or a skin substitute product after drug or biological; and

  9. Carried out:

    in subparagraph (B), by inserting , and, with respect to a skin substitute product, a square centimeter after pertaining to liquids.

  10. Carried out:

    Section 1847A(c)(6) of the Social Security Act (42 U.S.C. 1395w–3a(c)(6)) is amended by adding at the end the following:(J) Skin substitute products.— (i) In general.— Subject to clause (ii), the term “skin substitute product”— (I) means a cellular, tissue, biological or synthetic material that— (aa) is applied to a wound and intended to remain within the wound bed; and (bb) is marketed pursuant …

  11. Carried out:

    Section 1847A(f)(2)(A) of the Social Security Act (42 U.S.C. 1395w–3a(f)(2)(A)) is amended by inserting (except that, beginning January 1, 2027, a drug or biological so described does not include a skin substitute product (as defined in subsection (c)(6)(J))) after products that are payable under this part as a drug or biological.

§ 1395w–3a(a)–(b)

§ 1395w–3a. Use of average sales price payment methodology

(a) Application

(1) In general [inserted: Except as provided in paragraph (2), this section shall apply—]

(A) [inserted: to payment for drugs and biologicals that are described in section 1395u(o)(1)(C) of this title and that are furnished on or after January 1, 2005; and]

(B) [inserted: to payment for skin substitute products (as defined in subsection (c)(6)(J)) that are furnished during the period beginning on January 1, 2027, and ending on December 31, 2030.]

[struck: Except as provided in paragraph (2), this section shall apply to payment for drugs and biologicals that are described in section 1395u(o)(1)(C) of this title and that are furnished on or after January 1, 2005.]

(2) Election This section shall not apply in the case of a physician who elects under subsection (a)(1)(A)(ii) of section 1395w–3b of this title for that section to apply instead of this section for the payment for drugs and biologicals.

(b) Payment amount

(1) In general Subject to paragraph (7) and subsections (d)(3)(C) and (e), the amount of payment determined under this section for the billing and payment code for a drug or biological (based on a minimum dosage unit) is, subject to applicable deductible and coinsurance—

(A) in the case of a multiple source drug (as defined in subsection (c)(6)(C)), 106 percent of the amount determined under paragraph (3) for a multiple source drug furnished before April 1, 2008, or 106 percent of the amount determined under paragraph (6) for a multiple source drug furnished on or after April 1, 2008;

(B) in the case of a single source drug or biological (as defined in subsection (c)(6)(D)), 106 percent of the amount determined under paragraph (4) or in the case of such a drug or biological product that is a selected drug (as referred to in section 1320f–1(c) of this title), with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), 106 percent of the maximum fair price (as defined in section 1320f(c)(3) of this title) applicable for such drug and a year during such period;[struck: or]

(C) in the case of a biosimilar biological product (as defined in subsection (c)(6)(H)), the amount determined under paragraph (8)[struck: .][inserted: ; or]

(D) [inserted: in the case of a skin substitute product (as defined in subsection (c)(6)(J)) furnished during the period beginning on January 1, 2027, and ending on December 31, 2030, $457 per square centimeter.]

(2) Specification of unit

(A) Specification by manufacturer The manufacturer of a drug or biological [inserted: or a skin substitute product ]shall specify the unit associated with each National Drug Code (including package size) as part of the submission of data under section 1396r–8(b)(3)(A)(iii) of this title or subsection (f)(2), as applicable.

(B) Unit defined In this section, the term “unit” means, with respect to each National Drug Code (including package size) associated with a drug or biological, the lowest identifiable quantity (such as a capsule or tablet, milligram of molecules, or grams) of the drug or biological that is dispensed, exclusive of any diluent without reference to volume measures pertaining to liquids[inserted: , and, with respect to a skin substitute product, a square centimeter]. For years after 2004, the Secretary may establish the unit for a manufacturer to report and methods for counting units as the Secretary determines appropriate to implement this section.

(3) Multiple source drug For all drug products included within the same multiple source drug billing and payment code, the amount specified in this paragraph is the volume-weighted average of the average sales prices reported under section 1396r–8(b)(3)(A)(iii) of this title or subsection (f)(2), as applicable, determined by—

(A) computing the sum of the products (for each National Drug Code assigned to such drug products) of—

§ 1395w–3a(c)–(d)

(b)(3)(A)(i)–(c)(6)(G) unchanged ·

(H) Biosimilar biological product The term “biosimilar biological product” means a biological product approved under an abbreviated application for a license of a biological product that relies in part on data or information in an application for another biological product licensed under section 262 of this title.

(I) Reference biological product The term “reference biological product” means the biological product licensed under such section 262 of this title that is referred to in the application described in subparagraph (H) of the biosimilar biological product.

(J) [inserted: Skin substitute products.—]

(i) [inserted: In general.—] [inserted: Subject to clause (ii), the term “skin substitute product”—]

(I) [inserted: means a cellular, tissue, biological or synthetic material that—]

(aa) [inserted: is applied to a wound and intended to remain within the wound bed; and]

(bb) [inserted: is marketed pursuant to section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act, or section 361 of the Public Health Service Act; and]

(II) [inserted: includes any products reimbursed pursuant to skin substitutes codes under this title at any time prior to January 1, 2027.]

(ii) [inserted: Exclusions.—] [inserted: The term “skin substitute product” does not include—]

(I) [inserted: any product that is intended to temporarily protect or cover the wound bed and be removed without resorption such as a dressing; or]

(II) [inserted: any product that does not meet the domestic sourcing and distribution requirements described in clause (iii), unless a waiver under clause (iv) is in effect with respect to such product.]

(iii) [inserted: Domestic sourcing and distribution requirements.—] [inserted: For purposes of clause (ii), the domestic sourcing and distribution requirements described in this clause are, with respect to a product described in clause (i), the following:]

(I) [inserted: All human cellular or tissue material contained in such product was donated by citizens or nationals of the United States, or aliens lawfully admitted for permanent residence in the United States, and any such donation was made within the United States in accordance with applicable Federal law.]

(II) [inserted: All harvesting and processing (as applicable) and all manufacturing of such product occurred exclusively within the United States, and such harvesting, processing, and manufacturing was performed in compliance with all applicable standards of the Food and Drug Administration and the American Association of Tissue Banks.]

(III) [inserted: The product is distributed solely by the entity holding the applicable clearance, approval, or registration for such product under section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act, or section 361 of the Public Health Service Act, and no intermediaries, or agents were involved in the distribution of such product to the furnishing provider, except that a third-party distributor that adheres to and is able to perform the contractual requirements associated with the scope of work and is qualified and able to adhere to the legal and regulatory requirements defined in the scope of work may be involved in such distribution.]

(IV) [inserted: The entity described in subclause (III) with respect to the product submits to the Secretary, in such form and manner as the Secretary shall specify (but not less frequently than annually), an attestation that the product meets each of the requirements under subclauses (I) through (III).]

(iv) [inserted: Waiver.—] [inserted: The Secretary may waive the requirements under clause (iii) with respect to a specific product, for a period not to exceed 180 days, if the Secretary determines that a domestic supply shortage exists and that a waiver is necessary to protect patient access to care.]

(d) Monitoring of market prices

(1) In general The Inspector General of the Department of Health and Human Services shall conduct studies, which may include surveys, to determine the widely available market prices of drugs and biologicals to which this section applies, as the Inspector General, in consultation with the Secretary, determines to be appropriate.

§ 1395w–3a(f)Quarterly report on average sales price(1)–(2)

(d)(2)–(f) unchanged ·

(1) In general For requirements for reporting the manufacturer’s average sales price (and, if required to make payment, the manufacturer’s wholesale acquisition cost) for the drug or biological under this section, see section 1396r–8(b)(3) of this title.

(2) Manufacturers without a rebate agreement under subchapter xix

(A) In general If the manufacturer of a drug or biological described in subparagraph (C), (E), or (G) of section 1395u(o)(1) of this title or in section 1395rr(b)(14)(B) of this title that is payable under this part has not entered into and does not have in effect a rebate agreement described in subsection (b) of section 1396r–8 of this title, for calendar quarters beginning on January 1, 2022, such manufacturer shall report to the Secretary the information described in subsection (b)(3)(A)(iii) of such section 1396r–8 of this title with respect to such drug or biological in a time and manner specified by the Secretary. For purposes of applying this paragraph, a drug or biological described in the previous sentence includes items, services, supplies, and products that are payable under this part as a drug or biological[inserted: (except that, beginning January 1, 2027, a drug or biological so described does not include a skin substitute product (as defined in subsection (c)(6)(J)))].

(B) Audit Information reported under subparagraph (A) is subject to audit by the Inspector General of the Department of Health and Human Services.

(C) Verification The Secretary may survey wholesalers and manufacturers that directly distribute drugs or biologicals described in subparagraph (A), when necessary, to verify manufacturer prices and manufacturer’s average sales prices (including wholesale acquisition cost) if required to make payment reported under subparagraph (A). The Secretary may impose a civil monetary penalty in an amount not to exceed $100,000 on a wholesaler, manufacturer, or direct seller, if the wholesaler, manufacturer, or direct seller of such a drug or biological refuses a request for information about charges or prices by the Secretary in connection with a survey under this subparagraph or knowingly provides false information. The provisions of section 1320a–7a of this title (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subparagraph in the same manner as such provisions apply to a penalty or proceeding under section 1320a–7a(a) of this title.

Rest of § 1395w–3a unchanged ·

42 U.S.C. § 1395x Definitions

+4 −2Shown
More for 42 U.S.C. § 1395x
Read § 1395xOnly this section
3 changes the bill asks for here, 3 carried out
  1. Carried out:

    in subparagraph (JJ), by striking and at the end;

  2. Carried out:

    in subparagraph (KK), by adding and at the end; and

  3. Carried out:

    by inserting after subparagraph (KK) the following new subparagraph:(LL) skin substitute products (as defined in section 1847A(c)(6)(J))..

§ 1395x(s)Medical and other health services(2)–(4)

Start of § 1395x to (s)(2)(HH) unchanged ·

(II) marriage and family therapist services (as defined in subsection (lll)(1)) and mental health counselor services (as defined in subsection (lll)(3)); and 3

(JJ) lymphedema compression treatment items (as defined in subsection (mmm));[struck: and]

(KK) multi-cancer early detection screening tests (as defined in subsection (nnn));[inserted: and]

(LL) [inserted: skin substitute products (as defined in section 1847A(c)(6)(J)).]

(3) diagnostic X-ray tests (including tests under the supervision of a physician, furnished in a place of residence used as the patient’s home, if the performance of such tests meets such conditions relating to health and safety as the Secretary may find necessary and including diagnostic mammography if conducted by a facility that has a certificate (or provisional certificate) issued under section 354 of the Public Health Service Act [42 U.S.C. 263b]), diagnostic laboratory tests, and other diagnostic tests;

(4) X-ray, radium, and radioactive isotope therapy, including materials and services of technicians;

Rest of § 1395x unchanged ·

Step through the changes